HLA-A*0201 & B2M & p53 (HMTEVVRHC)
HLA-A*0201 & B2M & p53 (HMTEVVRHC) 제품 목록
- 속성
Protein (2)
- 제품 라이브러리
온라인 (2)
- 종
Human (2)
- 태그
His Tag & Avi Tag (1)His Tag (1)
- 마커
Biotin-labeled (1)PE Labeled (1)
| 제품 번호 | 종 | 발현 시스템 | 제품 설명 | 단백질 구조 | 순도 | 특성 |
|---|---|---|---|---|---|---|
 Human | HEK293 | Biotinylated Human HLA-A*02:01&B2M&p53 (HMTEVVRHC) Complex Protein (Monomer, MALS verified) |  |  | ||
| Human | HEK293 | PE-Labeled Human HLA-A*02:01&B2M&p53 (HMTEVVRHC) Tetramer Protein | |
총 수량2
- 1
HLA-A*0201 & B2M & p53 (HMTEVVRHC)분자 배경
TP53 has been recognized as a tumor suppressor. 50% of cancers carry a TP53 mutation while many others affect other pathway components. High-copy numbers of WT p53 peptide-MHC class I complexes were detected on tumor cells as compared to low copies on normal cells. The Human HLA-A*0201 p53 (HMTEVVRHC) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and HMTEVVRHC peptide of the p53.
임상 약물 정보
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| Superoxide dismutase (Ube Industries) | r-hSOD; FKU-871 | Phase 2 Clinical | Ube Industries Ltd, Astellas Pharma Inc | Myocardial Ischemia; Diabetic Neuropathies | 상세 |
| Otaplimastat | SP-8203 hydrochloride; SP8203 HCL; SP-8203 | Phase 2 Clinical | Shin Poong Pharmaceutical Co Ltd | Stroke | 상세 |
| BMX-010 | BMX-010; MnTE-2-PyP; MnTE-2-PyP5+ | Phase 2 Clinical | Duke University | Acne Vulgaris; Rosacea; Psoriasis; Dermatitis, Atopic | 상세 |
| APB-102 | APB-102; AMT-162 | Phase 2 Clinical | University Of Massachusetts Medical School | Amyotrophic Lateral Sclerosis | 상세 |
| Rucosopasem manganese | GC-4711 | Phase 1 Clinical | Galera Therapeutics Inc | Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung | 상세 |
| Bis-choline tetrathiomolybdate | ATN-224; WTX-101; ALXN-1840 | Phase 1 Clinical | Wilson Therapeutics | Hepatolenticular Degeneration; Multiple Myeloma; Prostatic Neoplasms; Melanoma | 상세 |
| NAS150 | AEOL-10150; NAS150; NAS-150 | Phase 1 Clinical | Aeolus Pharmaceuticals | Supranuclear Palsy, Progressive; Idiopathic Pulmonary Fibrosis; Neoplasms; Lung Injury | 상세 |
| RAG-17 | RAG-17; RAG17 | Phase 1 Clinical | Amyotrophic Lateral Sclerosis | 상세 | |
| NI-005 | AP-101 (AL-S Pharma); NI-005 | Phase 1 Clinical | Al-S Pharma Ag | Amyotrophic Lateral Sclerosis | 상세 |
시판 약물 정보
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 가장 빠른 브랜드 이름 | 가장 빠른 승인 국가 | 가장 빠른 적응증 | 가장 빠른 승인 회사 | 가장 빠른 승인 날짜 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|---|---|---|---|---|
| Orgotein | Approved | Gt Biopharma Inc | Ontosein | Spain | Rheumatic Diseases; Cystitis; Radiation Injuries | null | 1996-01-01 | Cystitis; Radiation Injuries; Rheumatic Diseases | 상세 | |
| Cupric Sulfate/Manganese sulfate/Selenious acid/Zinc Sulfate | Approved | American Regent Inc | MULTRYS | United States | Dietary Supplement | American Regent Inc | 2020-07-02 | Dietary Supplement | 상세 | |
| Tofersen | ISIS-333611; BIIB-067; 99mTc-MAG3-BIIB067 | Approved | Ludwig Institute For Cancer Research, Ionis Pharmaceuticals Inc | QALSODY | United States | Amyotrophic Lateral Sclerosis | Biogen Ma Inc, Biogen Inc | 2023-04-25 | Amyotrophic Lateral Sclerosis | 상세 |
- 제품 목록
- 시판 약물 정보
- 임상 약물 정보